Video

Will Biosimilars Impact the Cost of Specialty Drugs?

Author(s):

Davy James, Managing Editor

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Related Videos
Young female pharmacist working in her large pharmacy. Placing medications, taking inventory. Lifestyle - Image credit: lubero | stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com
Image Credit: © utah51 - stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com
Image Credit: © RandyJay - stock.adobe.com
Image Credit: © nimito - stock.adobe.com
WCLC, lung cancer, NSCLC
MARIPOSA Study: Long-Term Outcomes and Next Steps for Amivantamab Plus Lazertinib in EGFR-Mutant NSCLC
Pharmacist helping patient -- Image credit: Clayton D/peopleimages.com | stock.adobe.com
The EMPOWER-Lung 1 Trial: Five-Year Outcomes of Cemiplimab Monotherapy in Advanced NSCLC
Related Content
FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors
October 11th 2024

FDA Approves Marstacimab-hncq for Adults, Adolescents With Hemophilia A or B Without Inhibitors

Aislinn Antrim, Assistant Managing Editor
Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment
September 26th 2024

Pharmacy Focus - Oncology Edition: Advancing Brain Cancer Research and Treatment

Early Parkinson Disease and the Potential Therapeutic Role of Lixisenatide
October 11th 2024

Early Parkinson Disease and the Potential Therapeutic Role of Lixisenatide

Kamila Dymala, PharmD, MBA, BCMTMS, PACS
Public Health Matters podcast logo
September 19th 2024

Public Health Matters: The Difference Between Misinformation and Disinformation, and How Information Can Inform Evidence-Based Decisions

A green medical center.
October 11th 2024

The Financial, Clinical, and Human Role of Specialty Pharmacies in Ambulatory Infusion Centers

George W. Kridner, PharmD
FDA Approval, Breast Cancer | Image Credit: B-design - stock.adobe.com
October 10th 2024

FDA Approves Inavolisib With Palbociclib and Fulvestrant for Breast Cancer

Ashley Gallagher, Associate Editor